University of California at San Francisco
Welcome,         Profile    Billing    Logout  
 141 Trials 
287 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rugo, Hope
CALGB-40503, NCT00601900: Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer

Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Active, not recruiting
3
394
US
Bevacizumab, ABP 215, ABP-215, ABP215, Alymsys, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Avzivi, Aybintio, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MB02, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-aybi, Bevacizumab-bvzr, Bevacizumab-equi, Bevacizumab-maly, Bevacizumab-onbe, Bevacizumab-tnjn, BP102, BP102 Biosimilar, CT P16, CT-P16, CTP16, Equidacent, FKB 238, FKB-238, FKB238, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, MB 02, MB-02, MB02, Mvasi, MYL-1402O, Onbevzi, Oyavas, PF 06439535, PF-06439535, PF06439535, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Laboratory Biomarker Analysis, Letrozole, CGS 20267, CGS-20267, CGS20267, Femara, Fempro, Questionnaire Administration, Tamoxifen Citrate, Apo-Tamox, Clonoxifen, Dignotamoxi, Ebefen, Emblon, Estroxyn, Fentamox, Gen-Tamoxifen, Genox, ICI 46,474, ICI 46474, ICI-46474, ICI46474, Jenoxifen, Kessar, Ledertam, Lesporene, Nolgen, Noltam, Nolvadex, Nolvadex-D, Nourytam, Novo-Tamoxifen, Novofen, Noxitem, Oestrifen, Oncotam, PMS-Tamoxifen, Soltamox, TAM, Tamax, Tamaxin, Tamifen, Tamizam, Tamofen, Tamoxasta, Tamoxifeni Citras, Zemide
National Cancer Institute (NCI)
Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v6, Stage IV Breast Cancer AJCC v6 and v7
06/14
05/25
ARTEST, NCT04869943 / 2021-002176-39: Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer

Terminated
3
52
Europe, US, RoW
Enobosarm, VERU-024, Exemestane, Mestane
Veru Inc.
Metastatic Breast Cancer
01/24
01/24
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Calendar Jan 2025 - Dec 2025: Pivotal data from ZEST trial for HER2-negative BRCA-mutated or triple-negative breast cancer
Active, not recruiting
3
43
Europe, Canada, Japan, US, RoW
Niraparib, Placebo
GlaxoSmithKline
Neoplasms, Breast
06/24
12/25
NCT03562637 / 2018-001438-16: Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC

Recruiting
3
668
Europe, US, RoW
adagloxad simolenin combined with OBI-821, Globo H IHC Assay, Standard of care treatment
OBI Pharma, Inc, OBI Pharma, Inc.
Triple Negative Breast Cancer
12/25
12/27
FLAMINGO-01, NCT05232916: Phase 3 Study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects

Recruiting
3
750
Europe, US
Placebo, GLSI-100
Greenwich LifeSciences, Inc.
Breast Cancer
12/26
12/26
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
CompassHER2 RD, NCT04457596: T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the Trial

Calendar Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer
Recruiting
3
1031
Canada, US
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.
Anatomic Stage IA Breast Cancer AJCC V8, Anatomic Stage II Breast Cancer AJCC V8, Anatomic Stage IIA Breast Cancer AJCC V8, Anatomic Stage IIB Breast Cancer AJCC V8, Anatomic Stage III Breast Cancer AJCC V8, Anatomic Stage IIIA Breast Cancer AJCC V8, Anatomic Stage IIIB Breast Cancer AJCC V8, Anatomic Stage IIIC Breast Cancer AJCC V8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC V8, Prognostic Stage IA Breast Cancer AJCC V8, Prognostic Stage IB Breast Cancer AJCC V8, Prognostic Stage II Breast Cancer AJCC V8, Prognostic Stage IIA Breast Cancer AJCC V8, Prognostic Stage IIB Breast Cancer AJCC V8, Prognostic Stage III Breast Cancer AJCC V8, Prognostic Stage IIIA Breast Cancer AJCC V8, Prognostic Stage IIIB Breast Cancer AJCC V8, Prognostic Stage IIIC Breast Cancer AJCC V8, Synchronous Bilateral Breast Carcinoma
01/28
05/35
FOENIX-MBC2 TAS-120-201, NCT04024436 / 2019-001164-30: A Study of TAS-120 in Patients With Metastatic Breast Cancer

Completed
2
168
Europe, Canada, US
Futibatinib, TAS-120, Futibatinib plus Fulvestrant
Taiho Oncology, Inc., Taiho Pharma Europe Limited, TAIHO ONCOLOGY INC.
Metastatic Breast Cancer, FGFR 1 High Amplification, FGFR2 Amplification
05/23
10/24
AVIATOR, NCT03414658: The Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer

Hourglass Mar 2019 - Dec 2019 : From trial for cancer (unspecified)
Active, not recruiting
2
100
US
Vinorelbine, Trastuzumab, Avelumab, Utomilumab
Adrienne G. Waks, Pfizer, Breast Cancer Research Foundation, Johns Hopkins University
Breast Cancer
05/23
05/25
ASPRIA, NCT04434040: Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC

Active, not recruiting
2
40
US
Atezolizumab, Tecentriq, Sacituzumab govitecan, Trodelvy, IMMU-132
Dana-Farber Cancer Institute, Genentech, Inc., Stand Up To Cancer
Breast Cancer, Triple Negative Breast Cancer, Residual Cancer, Circulating Tumor DNA
12/25
12/27
NCT03990896: Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

Recruiting
2
30
US
Talazoparib, Talzenna
Massachusetts General Hospital, Pfizer
Breast Cancer
07/25
12/25
NCT05079360: Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer

Withdrawn
2
200
US
Sabizabulin, Veru-111, Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator, exemestane
Veru Inc.
Metastatic Breast Cancer
03/24
05/24
NCT03941730: Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer

Active, not recruiting
2
5
US
Biopsy, BIOPSY_TYPE, Bx, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Therapeutic Estradiol, 17 Beta-Estradiol, Aquadiol, Climara, Dimenformon, Diogyn, Diogynets, Estrace, ESTRADIOL, Estraldine, Oestradiol, Ovocylin, Progynon, Vagifem
Mayo Clinic, National Cancer Institute (NCI)
Advanced Triple-Negative Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Recurrent Breast Carcinoma
07/26
07/26
InCITe, NCT03971409: Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

Recruiting
2
150
US
Anti-OX40 Antibody PF-04518600, PF-04518600, Avelumab, Bavencio, MSB-0010718C, MSB0010718C, Binimetinib, ARRY-162, ARRY-438162, MEK162, Utomilumab, PF 05082566, PF 5082566, PF-05082566, PF-2566, Liposomal Doxorubicin, Caelyx, Lipodox, Sacituzumab Govitecan, Trodelvy, Sacituzumab Govitecan-hziy
Hope Rugo, MD, Translational Breast Cancer Research Consortium, Hoosier Cancer Research Network, Array BioPharma, Pfizer, Breast Cancer Research Foundation, Johns Hopkins University, Gilead Sciences
Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Triple-Negative Breast Carcinoma, Unresectable Breast Carcinoma
06/25
06/25
TBCRC 044, NCT03095352: Pembrolizumab with Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients with Chest Wall Disease

Completed
2
70
US
Pembrolizumab, Carboplatin, Ribocarbo, Trastuzumab
Hope Rugo, MD, Mayo Clinic, Johns Hopkins University, Translational Breast Cancer Research Consortium, Massachusetts General Hospital, Merck Sharp & Dohme LLC
Breast Cancer, Chest Wall Disease
11/24
11/24
ATEMPT 2.0, NCT04893109: Adjuvant T-DM1 Vs TH

Recruiting
2
500
US
trastuzumab-emtansine, T-DM1, Kadcyla, Trastuzumab SC, Herceptin Hylecta, Paclitaxel, Taxol, Onxal
Dana-Farber Cancer Institute, Genentech, Inc.
Breast Cancer, HER2-positive Breast Cancer
05/25
05/28
Cornerstone001, NCT05163223: Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer

Terminated
2
10
US, RoW
AST-301(pNGVL3-hICD), AST-301, rhuGM-CSF, Leukine, Sargramostim, Placebo, Normal Saline, Pembrolizumab, Keytruda, Capecitabine, Xeloda
Aston Sci. Inc.
Breast Cancer
05/24
05/24
TBCRC 058, NCT06099769: A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer

Recruiting
2
201
US
Enzalutamide, Mifepristone, TPC
Memorial Sloan Kettering Cancer Center, Astellas Pharma US, Inc., Breast Cancer Research Foundation, Corcept Therapeutics
Metastatic Breast Cancer
10/27
10/27
ELEVATE, NCT05563220: Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer

Recruiting
1/2
400
Europe, US, RoW
Elacestrant, Alpelisib, Piqray, Everolimus, Afinitor, Ribociclib, Kisqali, Palbociclib, Ibrance, Capivasertib, Truqap, Abemaciclib, Verzenio
Stemline Therapeutics, Inc.
Breast Cancer, Metastatic Breast Cancer
12/24
08/26
NCT06215469: Portable Scalp Cooling System (PSCS) to Prevent Hair Loss for Breast Cancer Patients (Cooler Heads)

Recruiting
N/A
40
US
Amma Portable Scalp Cooling System (PSCS), Portable Scalp Cooling System (PSCS), Questionnaires
University of California, San Francisco, Cooler Heads Care Inc.
Breast Cancer, Early-stage Breast Cancer, Hair Loss, Alopecia, Chemotherapy-induced Alopecia
08/25
08/25
ENCORE, NCT06774027: Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer

Not yet recruiting
N/A
100
US
Specimen collection, Biospecimen collection, Non-Investigational Antibody-Drug Conjugates (ADC), Non-Investigational ADC, Medical Record Review, Medical Chart Review
University of California, San Francisco, Translational Breast Cancer Research Consortium, Gilead Sciences, Johns Hopkins University
HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, Metastatic Breast Cancer, HR+ HER2 Breast Cancer, Metastatic Triple Negative Breast Cancers, Metastatic Triple-Negative Breast Carcinoma
12/30
12/30
Wong, Rebecca
NCT05661409: Sugammadex as Rescue Therapy

Completed
4
71
US
Sugammadex, Placebo
Emory University, National Center for Advancing Translational Sciences (NCATS), Georgia Clinical & Translational Science Alliance (CTSA)
Neuromuscular Blockade
08/24
08/24
NCT04084548: Perioperative Lidocaine and Ketamine in Abdominal Surgery

Active, not recruiting
3
420
US
Lidocaine and ketamine, Lidocaine, Ketamine, Placebo
The Cleveland Clinic
Postoperative Pain
12/24
12/24
TALES, NCT03011684: Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial

Recruiting
3
144
US
Tamoxifen, Letrozole
University of California, San Francisco
Infertility
01/25
01/25
NatPro, NCT04551807: Natural Versus Programmed Frozen Embryo Transfer

Active, not recruiting
3
788
US
Modified natural cycle, Programmed cycle
JHSPH Center for Clinical Trials
Pregnancy Related, Pre-Eclampsia
04/25
08/25
ACTION-1, NCT05477576 / 2022-000507-12: Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Recruiting
3
288
Europe, Canada, US, RoW
RYZ101, Everolimus, Sunitinib, Octreotide, Lanreotide
RayzeBio, Inc., RayzeBio, Inc.
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET
12/25
07/28
NCT01761929: 5 Fraction Stereotactic Body Radiation Therapy for Oligometastases Regimen, for Extra-Cranial Oligometastases

Completed
2
138
Canada
Radiation: 50Gy in 5 fr (max) to 25 Gy in 5 fr (min). Dose adapted to deliver the highest dose level while respecting normal tissue tolerance
University Health Network, Toronto, Princess Margaret Hospital, Canada
Solid Tumors With Oligometastatic Spread
02/23
02/23
ASPIRE, NCT06588686: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

Recruiting
2
270
Europe, Canada, US, RoW
Buloxibutid, C21, Placebo
Vicore Pharma AB, Population Services International
Idiopathic Pulmonary Fibrosis (IPF)
02/27
03/27
NCT04467515: A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer

Terminated
1/2
13
Canada, US
CAM-H2
Precirix
Advanced/Metastatic HER2-positive Breast, Gastric, Gastroesophageal Junction Cancer With Disease Progression Following Anti-HER2 Standard of Care Treatment
12/23
12/23
NCT01428895: Femoral Bone Metastases

Recruiting
N/A
180
Canada
Surgery Alone, Combined Surgery and Radiation therapy
University Health Network, Toronto
Cancer, Metastatic Malignant Neoplasm to Femur, Risk of Fracture
02/25
02/25
S-C-PATHY, NCT06390657: Radiotherapy Treatment Planning Comparison Using SBRT-PATHY (Photons) Versus CARBON-PATHY for Unresectable Bulky Tumors

Not yet recruiting
N/A
20
Europe
Planning CT, MRI
EBG MedAustron GmbH, The Princess Margaret Cancer Foundation
Cancer
12/25
12/25
MDS & PRRT, NCT06510868: Evaluating Myelodysplastic Syndrome Risks in NET Patients Planned for Peptide Radionuclide Therapy

Not yet recruiting
N/A
45
Canada
Peptide receptor radionuclide therapy (PRRT), Blood collection
University Health Network, Toronto
Myelodysplastic Syndrome, Acute Myeloid Leukemia
04/28
06/29
NCT01279408: Observing Patients With Palliative Asymptomatic Centrally Located Advanced Non-small Cell Lung Carcinoma (NSCLC)

Active, not recruiting
N/A
46
Canada
None: Questionnaire Study
University Health Network, Toronto
Non-small Cell Lung Carcinoma
11/28
11/28
Arean, Patricia A
NCT03516513: Participatory Design of Electronic Health Record Tools for Problem Solving Therapy

Completed
N/A
24
US
Problem Solving Therapy as Usual, Problem Solving Therapy, Assisted Problem Solving Therapy
University of Washington, National Institute of Mental Health (NIMH)
Depression
04/23
04/23
NCT04507360: Enhancing Engagement With Digital Mental Health Care

Active, not recruiting
N/A
570
US
Study 1, Generic Response, Study 1, Tailored Response, Study 1, Generic Resources, Study 1, Tailored Resources by Desired Resources, Study 1, Embedded single-question DIY, Study 1, Embedded full DIY within content page, Study 1, Single question plus full DIY, Study 1, Content-as-usual, Study 2, Control, Study 2, DIY tool without AI, Study 2, DIY tool with AI, Study 1, Tailored Resources by Demographics
University of Washington, Mental Health America, Talkspace, National Institute of Mental Health (NIMH)
Engagement, Patient
08/24
11/24
Rosenthal, Philip
NCT06165341: Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)

Recruiting
3
50
Europe, Canada, US
Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo
Takeda
Alpha1-Antitrypsin Deficiency
08/28
08/28
NCT05677971: Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

Recruiting
3
160
Europe, Canada, US, RoW
Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo, Sodium chloride
Takeda, Takeda Development Center Americas, Inc.
Alpha1-Antitrypsin Deficiency
03/27
03/29
RISE, NCT04729751 / 2020-004628-40: A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).

Completed
2
27
Europe, US, RoW
Maralixibat, Formerly LUM001 and SHP625
Mirum Pharmaceuticals, Inc.
Progressive Familial Intrahepatic Cholestasis, Alagille Syndrome, Cholestatic Liver Disease
12/24
12/24
TRIUMPH, NCT04862221: TReatment for ImmUne Mediated PathopHysiology

Recruiting
2
163
US
High-dose methylprednisolone, Solu-Medrol, Equine anti-thymocyte globulin, ATGAM, Prednisolone, 15 mg/mL oral solution National Drug Code: 62135-250-37, Placebo for prednisolone, Placebo for infusions, 0.9% Sodium chloride, Diphenhydramine, Benadryl, Methylprednisolone
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Ann & Robert H Lurie Children's Hospital of Chicago
Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy, Acute Liver Injury, Immune Dysregulation
01/26
01/27
DRUMARS, NCT04969185: Association Between Drug Levels, Malaria, and Antimalarial Resistance in the Setting of Seasonal Malaria Chemoprevention

Completed
N/A
310
RoW
University of California, San Francisco, Institut de Recherche en Sciences de la Sante, Burkina Faso
Malaria,Falciparum
11/21
05/23
Munster, Pamela N
RENAVIV, NCT03592472 / 2018-001495-38: A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma

Recruiting
3
413
Europe, US, RoW
Pazopanib, Votrient®, Abexinostat, PCI-24781, Placebo
Xynomic Pharmaceuticals, Inc.
Renal Cell Carcinoma
12/24
06/25
BRCA-P, NCT04711109 / 2017-002505-35: Studying the Effect of Denosumab on Preventing Breast Cancer in Women with a BRCA1 Germline Mutation

Active, not recruiting
3
300
US
Denosumab, Placebo, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Austrian Breast & Colorectal Cancer Study Group (ABCSG)
BRCA1 Mutation, Breast Cancer, Breast Diseases, Breast Neoplasms, Breast Carcinoma, Neoplasms
07/27
12/33
NCT04190056: Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer

Terminated
2
1
US
Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Tamoxifen, Vorinostat, L-001079038, MSK-390, SAHA, Suberanilohydroxamic Acid, Suberoylanilide Hydroxamic Acid, Zolinza
University of California, San Francisco, Merck Sharp & Dohme LLC
Anatomic Stage IV Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8
06/23
06/23
NCT03997968: A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

Completed
1/2
169
US
CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine, CYT-0851 in combination with rituximab and bendamustine
Cyteir Therapeutics, Inc.
Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, Head and Neck Cancer, DLBCL, Mantle Cell Lymphoma, Follicular Lymphoma, Pancreatic Cancer, CLL, Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer
11/24
12/24
ATLAS-101, NCT04503265: A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

Recruiting
1/2
122
US
AMXI-5001:Dose Escalation Phase I, Phase I, Dose Escalation, AMXI-5001:Dose Expansion Phase II, Phase II, Dose Expansion
AtlasMedx, Incorporated
Advanced Malignant Neoplasm, Breast Cancer, Ovarian Cancer, Homologous Recombination Deficiency, Prostate Cancer, Pancreatic Cancer
08/26
10/26
NCT06077877: A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors

Recruiting
1/2
135
Canada, US
GSK4524101, Niraparib
GlaxoSmithKline
Neoplasms
12/27
11/29
DF1001-001, NCT04143711 / 2019-004706-10: Study of DF1001 in Patients With Advanced Solid Tumors

Recruiting
1/2
378
Europe, US
DF1001, Nivolumab, Nab paclitaxel, Sacituzumab Govitecan-hziy
Dragonfly Therapeutics, Dragonfly Therapeutics, Inc.
Solid Tumor, Adult
10/26
12/26
Biolen-PC, NCT04284761: A Study to Establish the Feasibility of Biolen for the Local Delivery of Bicalutamide in Patients With Prostate Cancer

Completed
1
17
US, RoW
Bicalutamide implant
Alessa Therapeutics Inc.
Prostate Adenocarcinoma, Lower Urinary Tract Symptoms
05/23
05/23
NCT04257110: A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors

Active, not recruiting
1
208
US, RoW
BB-1701
Bliss Biopharmaceutical (Hangzhou) Co., Ltd
Locally Advanced/Metastatic HER2 Positive Solid Tumors
08/24
12/24
NCT04418167: JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

Suspended
1
71
US
JSI-1187, Dabrafenib, TAFINLAR
JS InnoPharm, LLC
Solid Tumors
06/24
12/24
NCT04678648: A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

Recruiting
1
134
US
RSC-1255 Dose Escalation, Phase 1a, Dose Escalation, RSC-1255 Dose Expansion, Phase 1b, Dose Expansion
RasCal Therapeutics, Inc.
Advanced Malignant Solid Neoplasm, RAS Mutation, Lung Cancer, Colon Cancer, Glioblastoma, Pancreatic Cancer
07/25
09/25
NCT01543763: Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors

Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Checkmark ASCO 2014
More
Active, not recruiting
1
90
US
PZP115891, PCI-24781, abexinostat, S 78454, GW786034, Votrient™, Pazopanib
Pamela Munster, Pharmacyclics LLC., Novartis, Xynomic Pharmaceuticals, Inc., GlaxoSmithKline Research and Education Foundation for Cardiovascular Disease
Metastatic Solid Tumors
01/24
12/24
NCT06177171: Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

Recruiting
1
18
US
Olaparib, LYNPARZA, ASTX727, INQOVI, C-DEC
Pamela Munster, National Cancer Institute (NCI)
BRCA1 Mutation, BRCA2 Mutation, BRCA Mutation, PALB2 Gene Mutation, Checkpoint Kinase 2 Gene Mutation, ATM Gene Mutation
01/26
11/26
NCT04774952: Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors

Active, not recruiting
1
108
US
RMC-5552
Revolution Medicines, Inc.
Solid Tumors
03/24
03/24
SGNSTNV-001, NCT04665921: A Study of SGN-STNV in Advanced Solid Tumors

Terminated
1
111
Europe, Canada, US
SGN-STNV
Seagen Inc.
Carcinoma, Non-Small Cell Lung, HER2 Negative Breast Neoplasms, Ovarian Neoplasms, Uterine Cervical Neoplasms, Endometrial Neoplasms, Esophageal Neoplasms, Gastroesophageal Junction Carcinoma, Stomach Neoplasms, Colorectal Neoplasms, Exocrine Pancreatic Adenocarcinoma, Appendiceal Adenocarcinoma, Pseudomyxoma Peritonei
03/24
03/24
NCT05838768: Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.

Recruiting
1
327
Europe, Japan, US, RoW
HRO761, pembrolizumab, irinotecan
Novartis Pharmaceuticals
MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers
05/29
05/29
NCT05277051: First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Recruiting
1
141
Europe, Canada, Japan, US, RoW
GSK4381562, Dostarlimab, Belrestotug, Nelistotug, GSK5764227
GlaxoSmithKline
Neoplasms
09/28
09/28
NCT05694715: Combination Therapy in Cancers With Mutations in DNA Repair Genes

Recruiting
1
24
US
Niraparib, Zejula, Small molecule inhibitor, Irinotecan, Camptosar, Irinotecan hydrochloride, CPT-11
University of California, San Francisco, GlaxoSmithKline
Metastatic Solid Tumor, BRCA1 Mutation, BRCA2 Mutation, ATM Gene Mutation, PALB2 Gene Mutation
01/28
01/28
NCT05058846: Pilot Study of Pancreatic Cancer Screening

Recruiting
N/A
250
US
Biospecimen Collection, Biological Sample Collection, Magnetic Resonance Cholangiopancreatography, MRCP, Magnetic Resonance Imaging, Magnetic Resonance Imaging Scan, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Endoscopic ultrasound, EUS, Questionnaires, Surveys
University of California, San Francisco
Pancreatic Carcinoma
01/32
01/32
Daud, Adil
KEYNOTE-C86, NCT04993677 / 2021-002037-42: A Study of SEA-CD40 Given With Other Drugs in Cancers

Active, not recruiting
2
77
Europe, Canada, US
SEA-CD40, pembrolizumab (KEYTRUDA®), pemetrexed, Alimta, carboplatin, Paraplatin
Seagen Inc., Merck Sharp & Dohme LLC
Melanoma, Carcinoma, Non-Small- Cell Lung
01/24
10/25
NCT05060003: Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection

Terminated
2
7
US
Atezolizumab, Tecentriq, Tiragolumab, Signatera Assay
Washington University School of Medicine, Genentech, Inc.
Stage II Melanoma
11/23
11/23
OMNIA-1, NCT05578872 / 2021-006711-29: A Study of ANV419 Alone or in Combination with Approved Treatment in Patients with Cutaneous Melanoma ().

Completed
1/2
29
Europe, US
ANV419, Pembrolizumab, Ipilimumab
Anaveon AG, Anaveon AG
Melanoma (Skin), Cutaneous Melanoma, Adult Disease, Advanced Solid Tumor, Metastatic Melanoma
08/24
08/24
SGNBB228-001, NCT05571839: A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors

Recruiting
1
275
Europe, Canada, US
PF-08046049
Seagen Inc.
Cutaneous Melanoma, Non-small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Neoplasms, Mesothelioma
11/26
11/27
NCT05695898: XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Therapy

Active, not recruiting
1
6
US
XmAb22841, CTLA-4 X LAG3, Bavunalimab, XmAb23104, PD1 X ICOS, XmAb104
University of California, San Francisco, Xencor, Inc.
Metastatic Melanoma, Advanced Melanoma
12/25
12/25
NCT05105100: Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma

Recruiting
N/A
25
US
Biopsy, Excisional Biopsy, Biospecimen Collection, Specimen Collection
University of California, San Francisco, Merck Sharp & Dohme LLC
Melanoma, Advanced Melanoma
08/26
08/26
Martin, Thomas G
BMTCTN1902, NCT05032820: MM CAR-T to Upgrade Response

Active, not recruiting
2
40
US
Lenalidomide and bb2121, ide-cel, revlimid
Marcelo Pasquini, MD, National Heart, Lung, and Blood Institute (NHLBI), Blood and Marrow Transplant Clinical Trials Network, National Cancer Institute (NCI), National Marrow Donor Program, Celgene a wholly owned subsidiary of BMS
Multiple Myeloma
01/25
04/25
CFT7455-1101, NCT04756726: Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

Recruiting
1/2
224
US
cemsidomide, CFT7455, Dexamethasone Oral
C4 Therapeutics, Inc.
Multiple Myeloma, Lymphoma, Non-Hodgkin's
09/25
12/25
NCT06348108: Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Not yet recruiting
1
38
US
Talquetamab, Anti-CD3/Anti-GPRC5D Bispecific Monoclonal Antibody JNJ-64407564, DuoBody Antibody JNJ-64407564, Iberdomide, CELMoD, CC-220, 1323403-33-3, Dexamethasone, Decadron, DexPak, Hemady, Bone Marrow Biopsy, Biopsy
Thomas Martin, MD, Bristol-Myers Squibb, Janssen Research & Development, LLC
Multiple Myeloma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma
06/26
06/28
NCT02332850: Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma

Active, not recruiting
1
83
Canada, US
Isatuximab, SAR 650984, Carfilzomib, Kyprolis, PR-171, Dexamethasone, Orgadrone, Spersadex, Visumetazone
Thomas Martin, MD, Amgen, Sanofi
Multiple Myeloma
12/24
12/24
NCT05577000: Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma

Active, not recruiting
1
5
US
Manufactured Anti-BCMA CAR-T cells, Anti-BCMA CAR-T cells, Fludarabine, Fludara, Cyclophosphamide, Cytoxan
Thomas Martin, MD, Actavis Inc., University of California, Davis, Eugia Pharma Specialities Limited
Refractory Multiple Myeloma, Relapsed Multiple Myeloma
10/28
10/43
NCT04640584: C-Brace Prospective Registry

Recruiting
N/A
250
Europe, US, RoW
C-Brace, Microprocessor-controlled Stance and Swing Orthosis (MP-SSCO)
Otto Bock Healthcare Products GmbH
Pareses, Lower Extremity
04/26
04/26
NCT01351545: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Recruiting
N/A
99999
US
A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Center for International Blood and Marrow Transplant Research, National Marrow Donor Program
Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Autoimmune Diseases, Severe Aplastic Anemia
10/41
10/41
Fong, Lawrence
NCI-2017-01387, NCT02451423: Neoadjuvant Atezolizumab in Localized Bladder Cancer

Completed
2
23
US
Atezolizumab, MPDL3280A
Lawrence Fong, Genentech, Inc., The Bladder Cancer Advocacy Network, Conquer Cancer Foundation, National Cancer Institute (NCI), The V Foundation
Carcinoma, Transitional Cell
03/23
03/23
NCT03248570: Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects

Completed
2
26
US
Pembrolizumab, KEYTRUDA, MK-3475, Chemotherapy
University of California, San Francisco, Merck Sharp & Dohme LLC, National Cancer Institute (NCI)
Castration Resistant Prostatic Cancer, Metastatic Prostate Cancer
09/23
09/23
NCT04064190: Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition

Withdrawn
2
48
US
Vactosertib(TEW-7197)/ Durvalumab
MedPacto, Inc., AstraZeneca
Urothelial Carcinoma Recurrent, Advanced Urothelial Carcinoma
12/23
12/24
NCT03007732: Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT

Active, not recruiting
2
23
US
Pembrolizumab, MK-3475, Keytruda, SD-101, Toll-like receptor 9, Leuprolide acetate, Intermittent androgen deprivation therapy, Abiraterone Acetate, Prednisone, Stereotactic Body Radiation Therapy, SBRT
David Oh, Prostate Cancer Foundation, Merck Sharp & Dohme LLC, TriSalus Life Sciences, Inc.
Prostatic Neoplasms
08/25
08/25
NCT03821246: Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

Recruiting
2
68
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Tocilizumab, Actemra, Etrumadenant, AB928
David Oh, Genentech, Inc.
Prostate Adenocarcinoma, Prostate Cancer, Localized Prostate Cancer
02/25
02/25
NCT05018273: Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors

Completed
1
26
Europe, US
VB10.NEO, Atezolizumab, Tecentriq
Nykode Therapeutics ASA, Genentech, Inc., Vaccibody AS
Solid Tumors, Adult
10/24
10/24
Feng, Sandy
ELIMINATE, NCT06280950: Expanding Liver Transplant Immunosuppression Minimization Via Everolimus

Recruiting
2
340
US
Everolimus, Zortress, Tacrolimus (continued reduction), FK-506, FR-900506, Prograf, Prograft, Tacrolimus (maintain 50% reduction)
National Institute of Allergy and Infectious Diseases (NIAID)
Liver Transplant
06/27
06/29
NCT04803006: A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PANORAMA)

Recruiting
2
18
US
TCD601
ITB-Med LLC
Kidney Transplantation
07/27
07/30
LITMMUS-UCSF, NCT03654040: Liver Transplantation With Tregs at UCSF

Terminated
1/2
42
US
arTreg, donor alloantigen-reactive regulatory T cells, CD4+CD25+CD127[lo] Treg cells, leukapheresis, apheresis, cyclophosphamide, Cytoxan®, CTX, mesna, Mesnex®, everolimus, EVR, Afinitor®, Zortress®
National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN), PPD, Rho Federal Systems Division, Inc.
Liver Transplant
03/23
03/23
NCT05215288: Expanded Access for Use of ExoFlo in Abdominal Solid Organ Transplant Patients

No Longer Available
N/A
20
US
ExoFlo
Direct Biologics, LLC
Solid Organ Transplant Rejection, Organ Rejection Transplants, Organ Rejection
 
 
INTERLIVER, NCT03193151: Diagnostic and Therapeutic Applications of Microarrays in Liver Transplantation

Recruiting
N/A
300
Europe, Canada, US, RoW
liver biopsy
University of Alberta
Liver Dysfunction
12/25
12/26
Vincenti, Flavio
TASK, NCT02711826: Treg Therapy in Subclinical Inflammation in Kidney Transplantation

Completed
1/2
32
US
Polyclonal Regulatory T Cells, Polyclonal Tregs, polyTregs, Everolimus, Zortress, Tacrolimus, FK-506, FR-900506, Prograf, Mycophenolate mofetil, Cellcept, MMF, Mycophenolic acid, Myfortic, MPA, Acetaminophen, Tylenol, Diphenhydramine, Benadryl, Biopsy, Kidney, Kidney Biopsy, Blood Draw, Phlebotomy, Venipuncture, Leukapheresis, leukocytapheresis, IS regimen conversion, Everolimus Conversion
National Institute of Allergy and Infectious Diseases (NIAID), Clinical Trials in Organ Transplantation
Kidney Transplant, Adult Living Donor Kidney Transplant Recipients, Renal Transplant, Living Kidney Donor
08/23
08/23
NCT04066114: Treg Modulation With CD28 and IL-6 Receptor Antagonists

Completed
1/2
24
US
lulizumab pegol, BMS-931699, antithymocyte globulin (rabbit), ATG (rabbit), Thymoglobulin®, methylprednisolone, Solu-Medrol ®, tocilizumab, Actemra®, Prednisone, prednisone tablets, Rayos®, everolimus, Zortress®, belatacept, Nulojix®, mycophenolate mofetil, MMF, CellCept®, mycophenolic acid, Myfortic®
National Institute of Allergy and Infectious Diseases (NIAID), Bristol-Myers Squibb, Clinical Trials in Organ Transplantation
Living-Donor Kidney Transplant, Kidney Transplant Recipients
09/23
09/23
ATTAIN, NCT04827979: Daratumumab and Belatacept for Desensitization

Recruiting
1/2
15
US
daratumumab, Darzalex®, immunoglobulin G1 kappa human monoclonal antibody, IgG1k human mAb, belatacept, Nulojix®, Bone marrow aspiration
National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN), Bristol-Myers Squibb, PPD, Rho Federal Systems Division, Inc.
Highly Sensitized Prospective Kidney Transplant Recipients
03/27
04/28
Shaw, James AM
PREVAIL, NCT05202509 / 2021-005092-39: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

Active, not recruiting
3
9541
Europe, Canada, Japan, US, RoW
Obicetrapib, Placebo
NewAmsterdam Pharma, Monash University
Atherosclerotic Cardiovascular Disease
11/26
11/26
PMS-001, NCT05025241: An Open-Label Study of Oral NNZ-2591 in Phelan-McDermid Syndrome

Completed
2
18
US
NNZ-2591, Cyclo-L-Glycyl-L-2-Allylproline
Neuren Pharmaceuticals Limited
Phelan-McDermid Syndrome
11/23
11/23
PTHS-001, NCT05025332: An Open-Label Study of Oral NNZ-2591 in Pitt Hopkins Syndrome

Completed
2
16
US
NNZ-2591, Cyclo-L-Glycyl-L-2-Allylproline
Neuren Pharmaceuticals Limited
Pitt Hopkins Syndrome
02/24
05/24
AS-001, NCT05011851: An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome

Completed
2
17
RoW
NNZ-2591, Cyclo-L-Glycyl-L-2-Allylproline
Neuren Pharmaceuticals Limited
Angelman Syndrome
05/24
07/24
PWS-001, NCT05879614: An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome

Withdrawn
2
20
US
NNZ-2591, Cyclo-L-Glycyl-L-2-Allylproline
Neuren Pharmaceuticals Limited
Prader-Willi Syndrome
06/25
06/25
Bluestone, Jeffrey A
NCT03239470: Polyclonal Regulatory T Cells (PolyTregs) for Pemphigus

Terminated
1
5
US
Cohort 1: 1.0 x 10^8 PolyTregs, Polyclonal Regulatory T Cells, autologous PolyTregs, CD4+CD127lo/negCD25+ PolyTregs, Cohort 2: 2.5x10^8 PolyTregs
National Institute of Allergy and Infectious Diseases (NIAID), Autoimmunity Centers of Excellence, Rho Federal Systems Division, Inc.
Pemphigus Foliaceus, Pemphigus Vulgaris
12/20
01/23
Woodruff, Prescott
NCT02791542: Sorting and Expression Profiling of Airway Cells From Humans (The SEARCH Study)

Completed
N/A
32
US
University of California, San Francisco, National Heart, Lung, and Blood Institute (NHLBI), National Institute of Allergy and Infectious Diseases (NIAID)
Asthma
03/23
03/23
SPIROMICS, NCT01969344: Study of COPD Subgroups and Biomarkers

Active, not recruiting
N/A
2981
US
University of North Carolina, Chapel Hill, National Heart, Lung, and Blood Institute (NHLBI), COPD Foundation, Columbia University, Johns Hopkins University, National Jewish Health, Temple University, University of Alabama at Birmingham, University of California, Los Angeles, University of California, San Francisco, University of Illinois at Chicago, University of Iowa, University of Michigan, University of Utah, Wake Forest University
COPD, Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema
12/30
12/30
SOURCE, NCT05033990: SPIROMICS Study of Early COPD Progression

Recruiting
N/A
1000
US
Weill Medical College of Cornell University, National Heart, Lung, and Blood Institute (NHLBI), University of North Carolina, Chapel Hill, Columbia University, Johns Hopkins University, National Jewish Health, University of Alabama at Birmingham, University of California, Los Angeles, University of Illinois at Chicago, University of Iowa, University of Michigan, University of Utah, Wake Forest University Health Sciences, Temple University, University of California, San Francisco, COPD Foundation, Mayo Clinic
COPD, Early-Onset
01/25
04/25
TIP, NCT04628442: Tissue Immune Interaction in Nasal Polyposis

Recruiting
N/A
100
US
Sinonasal Debridement Procedure, Nasal Polyp Removal, Biopsy
University of California, San Francisco, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI)
Chronic Rhinosinusitis (Diagnosis), Chronic Rhinosinusitis With Nasal Polyps, Asthma
03/25
03/25
MIBAS, NCT06105710: Mechanistic Insights From Bronchoscopy Airway Samples

Recruiting
N/A
24
US
University of California, San Francisco, National Institute of Allergy and Infectious Diseases (NIAID)
Asthma
12/27
12/28
Wong, Michael
NCT06291857: A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine

Not yet recruiting
3
9320
RoW
CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant, COVID-19 and influenza combination, Novavax COVID-19 Vaccine, Novavax SARS-CoV-2 rS vaccine, tNIV Vaccine, Trivalent Nanoparticle Influenza Hemagglutinin Vaccine, Fluzone High Dose, Fluzone HD
Novavax
COVID-19
02/25
02/26
NCT03997435: FOLFOXIRI With or Without Intensification for Rectal Cancer

Recruiting
2
72
RoW
Control arm, Experimental arm
CCTU
Rectal Cancer
12/25
12/26
NCT06281678: A Study of IBI363 in Subjects with Advanced Solid Malignancies

Recruiting
2
178
US
IBI363
Innovent Biologics (Suzhou) Co. Ltd.
Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Renal Cell Cancer
03/26
12/26
 

Download Options